---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020362"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T14:34:00.599575+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Oragenics to host Neurotrauma Medicine webinar; will present ONP-002 mTBI update

## Summary
- Webinar scheduled for May 20, 2024, at 12:00 PM ET.
- Lead drug candidate ONP-002, a neurosteroid for mild TBI, to be discussed.
- Company to review preclinical/Phase I data and provide details on upcoming Phase II trial in acute/emergency settings.
- No financial results or regulatory milestones announced.

## SEC filing metadata
- accession: 0001493152-24-020362
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315224020362/0001493152-24-020362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315224020362/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020362
- JSON: https://secwatch.observer/filing/0001493152-24-020362.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.